Assembly Biosciences is a clinical-stage biotechnology company that is advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection. They are developing multiple drug candidates to increase cure rates in patients with chronic HBV. Additionally, they have a microbiome program focused on developing oral live biotherapeutics for diseases associated with the microbiome. This program includes a robust platform for strain identification and selection, as well as a patent-pending delivery system for targeted oral delivery of therapies. Assembly Biosciences is also developing product candidates for other disease indications.